Opening a niche for therapy

• Verfasst von: Mahnke, Karsten [VerfasserIn]
• Verfasst von: Skorokhod, Alexander [VerfasserIn]
• Verfasst von: Grabbe, Stefan [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Titel: Opening a niche for therapy
• Titelzusatz: local lymphodepletion helps the immune system to fight melanoma
• Verf.angabe: Karsten Mahnke, Alexander Skorokhod, Stefan Grabbe and Alexander H. Enk
• Jahr: 2014
• Umfang: 3 S.
• Fussnoten: Available online 8 December 2015 ; Gesehen am 22.07.2020
• Titel Quelle: Enthalten in: The journal of investigative dermatology
• Ort Quelle: Amsterdam : Elsevier, 1938
• Jahr Quelle: 2014
• Band/Heft Quelle: 134(2014), 7, Seite 1794-1796
• ISSN Quelle: 1523-1747
• DOI: doi:10.1038/jid.2014.100
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Kommentar zu: Fujiwara, Susumu: Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist
• K10plus-PPN: 1725299739

Abstract

In this issue, Fujiwara et al. report that local ablation of CD4+ T cells in a murine B16 melanoma model, together with concomitant activation of the immune system by OX40L, leads to complete rejection of the melanomas. Rejection was driven mainly by CD8+ T cells, which infiltrated the melanomas and secreted sizeable amounts of IFN-γ. However, CD8+ T-cell infiltration also caused the recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs). Although these cells did not prevent the rejection of the melanomas, in clinical settings the long-term repopulation of tumors by MDSCs may counteract successful treatment. Thus, local ablation of CD4+ leukocytes may improve anti-melanoma therapies in humans, but at the same time MDSC levels in the tumor cells have to be kept in check to ensure treatment success.